Long-term safety study of LUM-201 in children with growth hormone deficiency
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A parent or caregiver must sign consent, and the child must give assent if they can.
- You must have completed a previous pediatric LUM-201 study through at least the 12-month visit.
- You must be eligible to continue LUM-201 treatment based on the prior study and other trial rules.
- Your child must not have any other medical or genetic condition that the study doctor feels would add extra risk with LUM-201.
- Your child must not be on long-term medicines that affect how the body breaks down LUM-201 (CYP3A4-related medicines). Short-term (2 weeks or less) may be reviewed case-by-case.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This trial studies how different types of growth hormone treatment affect growth and metabolism in children with growth hormone deficiency. It helps compare standard treatment with a long-acting type and looks at growth and metabolic changes.
This study follows children who are short for their age and checks how safe and effective growth hormone is over the long term. It may help families understand expected benefits and side effects for their specific growth-related condition.
This study looks at how the body’s growth signals (growth hormone and related proteins) work in children. It may help researchers understand growth differences in kids who are healthy or have certain growth-related conditions.
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
This trial is for children who have already completed one year of treatment with LUM-201 in an earlier study. It continues to test the medicine's safety over a longer period, so children can keep receiving treatment.
Hear when a new Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.